Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07777133) titled 'A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants' on Aug. 18.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Healthy Female Participants
Intervention:
Drug: Navlimetostat
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 16, 2026
Target Sample Size: 6
Countries of Recruitment:
United States
Neth...